Myocet Liposomal (Doxorubicin Hydrochloride)

Doxorubicin Hydrochloride, the active ingredient in Myocet Liposomal, is an anthracycline antibiotic presented as a liposomal injection for intravenous use. It is employed in the treatment of metastatic breast cancer, ovarian cancer and multiple myeloma in adult patients.

GNH USA supplies Myocet Liposomal as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides cold‑chain logistics for injectable products. Customers benefit from reliable delivery, regulatory support and comprehensive product documentation.

Myocet Liposomal (doxorubicin hydrochloride) is used in the treatment of solid tumours and hematologic malignancies that respond to anthracycline‑based chemotherapy.

Metastatic breast cancer: improves disease control and overall survival in adult patients. Ovarian cancer: used in combination regimens for recurrent or refractory disease. Multiple myeloma: employed in relapsed or refractory settings as part of combination therapy.

Myocet Liposomal may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea and vomiting - Fatigue - Alopecia (hair loss) - Myelosuppression (decreased blood cell counts)

Serious or Rare Side Effects: - Cardiotoxicity (heart failure, reduced ejection fraction) - Severe neutropenia or febrile neutropenia - Secondary acute myeloid leukemia - Severe infusion‑related reactions (hypotension, bronchospasm)

Before initiating Myocet Liposomal therapy, clinicians should consider several precautionary measures to minimise risk.

Cardiac monitoring: baseline and periodic echocardiograms to detect early cardiotoxicity. Hematologic monitoring: complete blood counts before each infusion to assess myelosuppression. Renal and hepatic function: evaluate organ function as impairment may affect drug clearance. Pregnancy and lactation: avoid use unless benefits clearly outweigh potential fetal or neonatal risks. Concomitant cardiotoxic agents: review and limit use of other drugs that may increase cardiac injury. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Myocet Liposomal can interact with other medicines, influencing efficacy or toxicity.

Major Interactions (Avoid): - Concurrent anthracyclines: additive cardiotoxicity risk. - Combination with trastuzumab: heightened cardiac dysfunction. - Live vaccines: increased risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Cyclophosphamide: may increase myelosuppression. - Antifungal azoles (e.g., fluconazole): can alter doxorubicin metabolism. - Granulocyte colony‑stimulating factor (G‑CSF): may affect neutrophil recovery timing.